Ajo LP decreased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 50.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 829,259 shares of the biotechnology company’s stock after selling 860,053 shares during the period. Ajo LP owned about 1.91% of United Therapeutics Corporation worth $107,580,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of United Therapeutics Corporation by 4,222.8% during the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock valued at $641,969,000 after acquiring an additional 4,632,287 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of United Therapeutics Corporation by 144.0% during the second quarter. Wells Fargo & Company MN now owns 730,634 shares of the biotechnology company’s stock valued at $94,785,000 after acquiring an additional 431,210 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of United Therapeutics Corporation by 308.6% during the second quarter. JPMorgan Chase & Co. now owns 500,499 shares of the biotechnology company’s stock valued at $64,930,000 after acquiring an additional 378,002 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of United Therapeutics Corporation by 27.8% during the first quarter. AQR Capital Management LLC now owns 1,736,357 shares of the biotechnology company’s stock valued at $235,068,000 after acquiring an additional 377,395 shares during the last quarter. Finally, Schroder Investment Management Group raised its stake in shares of United Therapeutics Corporation by 42.8% during the second quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock valued at $143,359,000 after acquiring an additional 327,360 shares during the last quarter.

In related news, CEO Martine A. Rothblatt sold 1,234 shares of the stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $132.32, for a total value of $163,282.88. Following the completion of the transaction, the chief executive officer now directly owns 1,374 shares in the company, valued at approximately $181,807.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,247 shares of the stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $126.40, for a total transaction of $157,620.80. Following the completion of the transaction, the chief executive officer now owns 2,316 shares of the company’s stock, valued at $292,742.40. The disclosure for this sale can be found here. Insiders sold a total of 25,178 shares of company stock valued at $3,289,427 over the last 90 days. Company insiders own 7.80% of the company’s stock.

Shares of United Therapeutics Corporation (UTHR) opened at 120.65 on Tuesday. The firm has a 50-day moving average of $130.11 and a 200-day moving average of $130.35. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The firm has a market capitalization of $5.24 billion, a PE ratio of 13.99 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. During the same quarter last year, the company posted $4.42 earnings per share. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/ajo-lp-reduces-position-in-united-therapeutics-corporation-uthr.html.

UTHR has been the subject of several analyst reports. ValuEngine downgraded shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Jefferies Group LLC reaffirmed a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, June 8th. BidaskClub raised shares of United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, June 9th. UBS AG reaffirmed a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Six investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $134.50.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.